[go: up one dir, main page]

WO1992004048A3 - Inhibition du potentiel metastatique et du caractere envahissant de cellules tumorales grace a l'utilisation d'oligosaccharides et d'antigenes ou d'anticorps d'oligosaccharides - Google Patents

Inhibition du potentiel metastatique et du caractere envahissant de cellules tumorales grace a l'utilisation d'oligosaccharides et d'antigenes ou d'anticorps d'oligosaccharides Download PDF

Info

Publication number
WO1992004048A3
WO1992004048A3 PCT/US1991/006202 US9106202W WO9204048A3 WO 1992004048 A3 WO1992004048 A3 WO 1992004048A3 US 9106202 W US9106202 W US 9106202W WO 9204048 A3 WO9204048 A3 WO 9204048A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligosaccharides
antigens
metastasis potential
antibodies
invasiveness
Prior art date
Application number
PCT/US1991/006202
Other languages
English (en)
Other versions
WO1992004048A2 (fr
Inventor
Tatsushi Toyokuni
Sen-Itiroh Hakomori
Original Assignee
Biomembrane Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomembrane Inst filed Critical Biomembrane Inst
Priority to AU86677/91A priority Critical patent/AU659808B2/en
Publication of WO1992004048A2 publication Critical patent/WO1992004048A2/fr
Publication of WO1992004048A3 publication Critical patent/WO1992004048A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à des agents et à des procédés destinés à inhiber le potentiel métastatique de cellules tumorales. On peut inhiber le potentiel métastatique de cellules tumorales en utilisant un agent choisi dans le groupe composé: (a) d'antigènes d'hydrates de carbone associés à la tumeur (TACA) qui possèdent une importance prognostique différentielle; (b) d'anticorps qui se lient spécifiquement à ces antigènes; (c) de constituants oligosaccharides de ces antigènes; et (d) de conjugués de ces antigènes ou de ces oligosaccharides, l'agent ainsi formé ayant le pouvoir d'inhiber le potentiel métastatique de la préparation. Des oligosaccharides supplémentaires utilisables dans ces procédés et dans ces compositions sont constitués par le lactose et par des dérivés de lactose. L'invention décrit également des conjugués comprenant des oligosaccharides et du poly(éthylène glycol).
PCT/US1991/006202 1990-08-30 1991-08-29 Inhibition du potentiel metastatique et du caractere envahissant de cellules tumorales grace a l'utilisation d'oligosaccharides et d'antigenes ou d'anticorps d'oligosaccharides WO1992004048A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU86677/91A AU659808B2 (en) 1990-08-30 1991-08-29 Inhibition of metastasis potential and invasiveness by oligosaccharides or oligosaccharide antigens or antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57553990A 1990-08-30 1990-08-30
US575,539 1990-08-30
US72498391A 1991-07-02 1991-07-02
US724,983 1991-07-02

Publications (2)

Publication Number Publication Date
WO1992004048A2 WO1992004048A2 (fr) 1992-03-19
WO1992004048A3 true WO1992004048A3 (fr) 1992-10-01

Family

ID=27076723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006202 WO1992004048A2 (fr) 1990-08-30 1991-08-29 Inhibition du potentiel metastatique et du caractere envahissant de cellules tumorales grace a l'utilisation d'oligosaccharides et d'antigenes ou d'anticorps d'oligosaccharides

Country Status (5)

Country Link
EP (1) EP0546122A1 (fr)
JP (1) JPH06501008A (fr)
AU (1) AU659808B2 (fr)
CA (1) CA2089375A1 (fr)
WO (1) WO1992004048A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
JPH06503177A (ja) * 1991-06-26 1994-04-07 ザ　バイオメンブレイン　インスティテュート 抗―炭水化物抗体の組合せを利用しての肺癌の早期診断
US5639737A (en) * 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
WO1994001483A1 (fr) * 1992-07-02 1994-01-20 Collagen Corporation Conjugues polymeres biocompatibles
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE69624581T2 (de) * 1995-04-14 2003-05-15 Kazunori Kataoka Polyethylenoxide mit einer saccharidgruppe an einem ende und einer anderen funktionellen gruppe am anderem ende sowie verfahren zu deren herstellung
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228233A1 (de) * 1982-07-28 1984-02-02 Wolfgang Dr. 6500 Mainz Dippold Verwendung des antikoerpers r-24 und verfahren zur inhibierung des zellwachstums von melanomzellen
EP0249008A2 (fr) * 1986-05-09 1987-12-16 Pulverer, Gerhard, Prof. Dr.Dr.h.c. Utilisation de monosaccharides spécifiques pour la préparation d'un médicament pour la prévention des métastases de tumeurs malignes
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
EP0380084A2 (fr) * 1989-01-27 1990-08-01 The Biomembrane Institute Méthode d'inhibition des interactions cellule-cellule et cellule-substrat par blocage des interactions entre hydrates de carbone

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228233A1 (de) * 1982-07-28 1984-02-02 Wolfgang Dr. 6500 Mainz Dippold Verwendung des antikoerpers r-24 und verfahren zur inhibierung des zellwachstums von melanomzellen
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
EP0249008A2 (fr) * 1986-05-09 1987-12-16 Pulverer, Gerhard, Prof. Dr.Dr.h.c. Utilisation de monosaccharides spécifiques pour la préparation d'un médicament pour la prévention des métastases de tumeurs malignes
EP0380084A2 (fr) * 1989-01-27 1990-08-01 The Biomembrane Institute Méthode d'inhibition des interactions cellule-cellule et cellule-substrat par blocage des interactions entre hydrates de carbone

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
ANALYTICAL BIOCHEMISTRY, Vol. 131, 1983 Charles O. Beauchamp et al: "A New Procedure for the Synthesis of Polyethylene Glycol-Protein Adducts; Effects on Function, Receptor Recognition, and Clearance of Superoxide Dismutase, Lactoferrin, and alfa2-M", *
ANALYTICAL BIOCHEMISTRY, vol. 131, 1983; C.O. BEAUCHAMP et al., pp. 25-33/ *
CANCER COMMUNICATIONS, Vol. 2, No. 9, 1990 Hisao Oguchi et al: "Effect of Lactose Derivatives on Metastatic Potential of B16 Melanoma Cells ", *
CANCER COMMUNICATIONS, vol. 2, no. 9, 1990; H. OGUCHI et al., pp. 311-316/ *
CANCER RESEARCH, Vol. 46, July 1986 John G. Collard et al: "Cell Surface Sialic Acid and the Invasive and Metastatic Potential of T-Cell Hybridomas ", *
CANCER RESEARCH, vol. 46, July 1986; J.G. COLLARD et al., pp. 3521-3527/ *
CLIN.EXPL.METASTASIS, Vol. 6, No. 2, 1988 J. Beuth et al: "Inhibition of liver tumor cell colonization in two animal tumor models by lectin blocking with D-galactose or arabinogalactan ", *
CLINICAL EXPL. METASTASIS, vol. 6, no. 2, 1988; J. BEUTH et al., pp. 115-120/ *
DEVELOPMENTAL BIOLOGY, Vol. 122, 1987 Bruce A. Fenderson et al: "Glycolipid Core Structure Switching from Globo- to Lacto- and Ganglio-Series during Retinoic Acid-Induced Differentiation of TERA-2-Derived Human Embryonal Carcinoma Cells ", *
DEVELOPMENTAL BIOLOGY, vol. 122, 1987; B.A. FENDERSON et al., pp. 21-34/ *
Dialog Information Services, File 159, Cancerlit, Dialog accession no. 00575160, Iliopoulos D. et al: "Inhibition of metastases of a human melanoma xenograft by an anti-GD2/GD3 monoclonal antibody (meeting abstract)", Proc Annu Meet Am Assoc Cancer Res; 28:77 1987 *
DIALOG INFORMATION SERVICES, File 159, Medline 66-90/May, Medline AN 86255075; T. MORI et al., AN 00540856/ *
Dialog Information Services, File 159: Medline 66-90/May, accession no. 00540856, Medline accession no. 86255075, Mori T et al: "Heterophil forssman glycoprotein and adenovirus 12:transformed rat cell lines", & J Natl Cancer Inst; 77(1):115-20 1986 *
EXPERIMENTIA, Vol. 45, 1989 W. Roszkowski et al: "Blocking of lectin-like adhesion molecules on pulmonary cells inhibits lung sarcoma L-1 colonization in BALB/c-mice ", *
EXPERIMENTIA, vol. 45, 1989; W. ROSZKOWSKI et al., pp. 584-588/ *
J CANCER RES CLIN ONCOL, Vol. 113, 1987 J. Beuth et al: "Inhibition of liver metastasis in mice by blocking hepatocyte lectins with arabinogalactan infusions and D-galactose ", *
J. Nat. Cancer Inst., Vol. 71, No. 2, August 1983 Sen-itiroh Hakomori et al.: "Glycosphingolipids as Tumor-Associated and Differentiation Markers ", *
JOURNAL OF CANCER RESEARCH & CLINICAL ONCOLOGY, vol. 113, 1987; J. BEUTH et al., pp. 51-55/ *
JOURNAL OF CELL BIOLOGY, vol. 111, August 1990; I. CORNIL et al., pp. 773-781/ *
JOURNAL OF NATL. CANCER INST., vol. 71, no. 2, August 1983; H. SEN-ITIROH et al., pp. 231-251/ *
National Library of Medicine (NLM), File Medline, Medline accesion no. 90277512, Tsukada K: "Anti- metastatic and growth-inhibitory effects of N- acetylchitohexaose in mice bearing Lewis lung car- cinoma", Jpn J Cancer Res 1990 Mar; 81(3): 259-65 *
National Library of Medicine database, File Medline, NLM Accession no. 84106532, Dippold W.G. et al: "Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3- -gandlioside antibody", & Cancer Res 1984 Feb; 44(2):806-10 *
National Library of Medicine database, File Medline, NLM Accession no. 86277574, Katano M et al: "Human IgM monoclonal anti-GD2 antibody: reactivity to a human melanoma xenograft",& Jpn J Cancer Res 1986 Jun;77(6):584-94 *
National Library of Medicine database, File Medline, NLM Accession no. 87041518, Irie R.F. et al: "Regression of cutaneous meta- static melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2", & Proc Natl Acad Sci U S A 1986 Nov;83(22):8694-8 *
National Library of Medicine database, File Medline, NLM Accession no. 89141796, Iliopoulos D. et al: "Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides", & J Natl Cancer Inst 1989 Mar 15; 81(6);440-4 *
National Library of Medicine database, File Medline, NLM Accession no. 90025151, Muramatsu T: "Glycoproteins associated with meta- static potential of cancer:", & Gan To Kagaku Ryoho 1989 Oct; 16(10):3354-8 *
National Library of Medicine database, File Medline, NLM Accession no. 90187481, Hamanaka S et al: "Strong anti-tumor effect of monosialoganglioside specific monoclonal antibody 202: a clinical trial in a cancer patient with melanoma", & J Dermatol 1989 Dec;16(6):480-6 *
NATL. LIBRARY OF MEDICINE DATABASE, File Medline; D. ILIOPOULOS et al., AN 89141796; and T. MURAMATSU, AN 90025151; and M. KATANO et al., AN 86277574; and R.F. IRIE et al., AN 87041518; and S. HAMANAKA et al., AN 90187481; and W.G. DIPPOLD et al., AN 84106532/ *
THE JOURNAL OF CELL BIOLOGY, Vol. 111, August 1990 Isabelle Cornil et al: "Tumor Cell Surface beta1-4-Linked Galactose Binds to Lectin(s) on Microvascular Endothelial Cells and Contributes to Organ Colonization ", *
ZBL. BAKT., vol. 274, 1990; J. BEUTH et al., pp. 350-358/ *
ZBL.BAKT., Vol. 274, 1990 J. Beuth et al: "Lectins: Mediators of Adhesion for Bacteria in Infections Diseases and for Tumor Cells in Metastasis ", *
ZEITSCHRIFT F~R NATURFORSCHUNG. Section C. Biosciences, Vol. 38, 1983 Enrico Boccu et al: "Coupling of Monomethoxypolyethyleneglycols to Proteins via Active Esters ", *
ZEITSCHRIFT FÜR NATURFORSCHUNG, Section C, Biosciences, vol. 38, 1983; E. BOCCU et al., pp. 94-99/ *

Also Published As

Publication number Publication date
WO1992004048A2 (fr) 1992-03-19
AU659808B2 (en) 1995-06-01
JPH06501008A (ja) 1994-01-27
CA2089375A1 (fr) 1992-03-01
AU8667791A (en) 1992-03-30
EP0546122A1 (fr) 1993-06-16

Similar Documents

Publication Publication Date Title
CA2218246A1 (fr) Synthese enzymatique de liaisons glycosidiques
IL125928A0 (en) Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and pharmaceutical compositions for inhibiting the same
AU3835285A (en) Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
FI935396L (fi) Uudet nanopartikkelien muodossa olevat, veren röntgenvarjoainekoostumukset, joissa on suuren molekyylipainon pinta-aktiivista ainetta
NL191308C (nl) Gelyofiliseerd, na oplossing injecteerbaar preparaat dat een antracycline-glycoside bevat, alsmede werkwijze voor de bereiding van een injecteerbare oplossing van een antracycline-glycoside.
CA2066728A1 (fr) Preparation anti-tumorale composee d'interleukine-2 et d'histamine, leurs analogues ou agonistes des recepteurs h2
HRP20020330B1 (fr)
ZA200202184B (en) Fucosylated oligosaccharides and process for their preparation.
WO1992018610A3 (fr) Compositions et procedes de liaison endotheliale
KR930007882A (ko) 세포독성 비시클로[7.3.1]트리데 - 4 - 센 - 2,6디인 화합물 및 그의 제조방법
AU2407899A (en) Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it
WO1992004048A3 (fr) Inhibition du potentiel metastatique et du caractere envahissant de cellules tumorales grace a l'utilisation d'oligosaccharides et d'antigenes ou d'anticorps d'oligosaccharides
WO1997029199A3 (fr) Peptides pour l'antigene prostatique specifique et leurs utilisations
CZ16395A3 (en) Inclusion complexes of nimesulid salts of alkali metals and alkaline earth metals with cyclodextrins, process of their preparation and pharmaceutical compositions containing thereof
BG100863A (en) Fibrin-specifil antibody and its use as an antithrombotic agent
BG103735A (en) Method for the preparation of substituted thiazolidindions
EP0490816A3 (en) Fluoro-compounds
EP0274444A3 (fr) Complexes d'ibuprofène en solution, compositions et procédés pour leur préparation
AU1337783A (en) New fibrionoltic enzymes
IE781659L (en) Pseudotrisaccharides
IL99446A0 (en) Heteroarylmethylbenzenes
AU6182994A (en) Bifunctional glycoproteins having a modified carbohydrate complement, and their use in tumor-selective therapy
WO1991019725A3 (fr) Analogues heterocycliques d'anthracycline et d'anthracyclinone
WO2000058328A3 (fr) Derive d'avermectine
WO1999007718A3 (fr) Derives substitues du tetrahydropyrane, leur procede de production, leur utilisation comme medicaments ou agents diagnostiques, et medicaments les contenant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2089375

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991919388

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991919388

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991919388

Country of ref document: EP